Here we describe a novel platform that enables the production of two full length IgG molecules from a single production cell line. This technology was achieved using a molecular engineering approach to precisely control the cognate pairing of antibody heavy chains and light chains during the assembly of two antibodies in the same cell line. This technology platform, which has been designated as MabPair, can be applied for the development of therapeutic antibody products that contain a mixture of two different antibodies. The antibody cocktail is produced by the same cell line in a predefined ratio and can be manufactured using a conventional antibody production process. When addressing multiple targets, MabPair products can offer significant advantages and flexibility over a bispecific antibody. MabPair technology represents a novel approach for developing antibody combination products. This approach is exemplified by the development of PSB205, our lead MabPair product candidate. PSB205 targets two immune checkpoint pathways, PD-1 and CTLA-4. The development of PSB205, as a potential anti-cancer immunotherapeutic, is discussed.

Citation Format: William C. Fanslow, Zhi Liu, Zhonghua Hu, Hua Liu, Min Shen, Yufeng Peng, Cristina Domeier, David Treiber, Ron Schoner, Wei Yan. Development of PSB205, a bifunctional MabPair product that targets PD-1 and CTLA-4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4069.